Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Torrent Pharmaceuticals Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,491 | 2,591 | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 |
| Expenses + | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 |
| Operating Profit | 727 | 791 | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 |
| OPM % | 29% | 31% | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% |
| Other Income + | 9 | 34 | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 |
| Interest | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 |
| Depreciation | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 |
| Profit before tax | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 |
| Tax % | 34% | 29% | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% |
| Net Profit + | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 |
| EPS in Rs | 8.48 | 11.17 | 11.41 | 13.09 | 13.27 | 13.50 | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 | 18.76 | 10.76 |
Financials of Torrent Pharmaceuticals Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| Expenses + | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 9,421 |
| Operating Profit | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 4,559 |
| OPM % | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% |
| Other Income + | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -183 |
| Interest | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 385 |
| Depreciation | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 1,119 |
| Profit before tax | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 |
| Tax % | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | 26% |
| Net Profit + | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 |
| EPS in Rs | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.17 |
| Dividend Payout % | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% | 0% |
Financials of Torrent Pharmaceuticals Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 |
| Reserves | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,220 |
| Borrowings + | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 15,025 |
| Other Liabilities + | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 20,898 |
| Total Liabilities | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 44,312 |
| Fixed Assets + | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 33,376 |
| CWIP | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 457 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 949 |
| Other Assets + | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 9,530 |
| Total Assets | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 44,312 |
Financials of Torrent Pharmaceuticals Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Cash from Investing Activity + | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 | -12,713 |
| Cash from Financing Activity + | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 | 10,151 |
| Net Cash Flow | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 | 461 |
| Free Cash Flow | 574 | 2,150 | 523 | 105 | 1,138 | 990 | 1,671 | 1,607 | 1,953 | 2,967 | 1,991 | 2,387 |
| CFO/OP | 85% | 121% | 101% | 87% | 105% | 77% | 88% | 91% | 97% | 112% | 86% | 84% |
Financials of Torrent Pharmaceuticals Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 | 79 |
| Inventory Days | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 | 338 |
| Days Payable | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 | 254 |
| Cash Conversion Cycle | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 | 163 |
| Working Capital Days | 29 | -1 | 28 | -80 | -62 | -52 | -5 | 7 | -33 | -27 | 7 | -3 |
| ROCE % | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% | 15% |